Single Extracellular Vesicle Transmembrane Protein Characterization by Nano-Flow Cytometry
July 26th, 2022
The latest generation of EV characterization tools are capable of single EV analysis across multiple parameters simultaneously. Nano-flow cytometry measures all biological particles larger than 45 nm without labeling and identifies specific characteristics of subpopulations by a variety of fluorescent labeling techniques.
Overview
This study focuses on the characterization of extracellular vesicles (EVs) using Nano-Flow Cytometry, a method capable of analyzing subpopulations of EVs in a label-free manner. By employing this technique, researchers can develop robust datasets that minimize false positives while analyzing EVs derived from diverse biological sources.
Key Study Components
Research Area
- Extracellular vesicles (EV) analysis
- Particle characterization and classification
- Label-free measurement techniques
Background
- Challenges in EV characterization often require multiple instruments.
- Nano-Flow Cytometry offers a simultaneous measurement of EV characteristics.
- Applications extend to viruses, lipid nanoparticles, and nanomaterials.
Methods Used
- Nano-Flow Cytometry for single EV analysis
- Measurement of particles larger than 14 nanometers
- Optimization of fluorescence labeling protocols
Main Results
- Individual measurement of EVs enhances data accuracy.
- Key parameters for reliable analysis are established.
- Systematic approach reduces false positives, enhancing result validity.
Conclusions
- This study demonstrates the efficacy of Nano-Flow Cytometry in EV analysis.
- The approach is significant for advancing biological research on EVs.
Frequently Asked Questions
Executive Industry Relevance
Single extracellular vesicle (EV) transmembrane protein characterization by nano-flow cytometry (nFCM) enables high-resolution, quantitative profiling of EV subpopulations at the single-particle level. This capability advances predictive confidence in early discovery and target validation by providing robust, multi-parameter datasets that minimize false positives and support mechanistic de-risking. nFCM’s throughput and quantitative outputs position it as a reusable platform for portfolio-wide EV biomarker and functional studies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables quantitative interrogation of EV surface markers for functional target validation.
- Supports mechanistic de-risking by distinguishing EV subpopulations based on marker expression.
- Provides robust, single-particle data to inform predictive confidence and triage decisions.
Screening & Assay Development
- Delivers standardized, reproducible quantification of EV size, concentration, and marker positivity.
- Facilitates assay development by enabling rapid, high-throughput analysis of labeled and unlabeled EVs.
- Supports screening readiness by providing quantitative outputs in particles/mL and percentage marker positivity.
Translational & Preclinical Research
- Allows alignment of EV marker profiles with disease-relevant systems when appropriate markers are selected.
- Enables continuity from discovery through preclinical validation by supporting quantitative biomarker assessment.
- Reduces biological ambiguity in translational studies by providing multi-parameter EV characterization.
Pipeline & Workflow Integration
nFCM integrates into the discovery-to-preclinical continuum by enabling single-particle EV analysis for hypothesis testing, assay development, and translational biomarker studies.
- Discovery Biology: Supports hypothesis testing and pathway clarification through quantitative EV marker profiling.
- Screening: Provides reproducible, quantitative outputs for assay standardization and compound evaluation.
- Analytics: Delivers size, concentration, and fluorescence-based marker data for comparative analysis.
- Translational Research: Facilitates biomarker alignment and preclinical continuity when disease-relevant markers are used.
- Enterprise Reuse: Functions as a platform technology for diverse EV and nanoparticle characterization needs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in EV studies.
- Operational Value: Standardizes and streamlines EV characterization with high throughput and reproducibility.
- Strategic Value: Improves go/no-go decisions and capital efficiency by providing robust, quantitative data.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of EV-based discovery programs.
Implementation Considerations
- Requires expertise in fluorescence labeling and flow cytometry data analysis.
- Needs access to specialized nFCM instrumentation and analytical software.
- Demands cross-team standardization of labeling protocols and data interpretation.
- Adaptable to various EV sources and labeling targets, supporting broad applicability.
- Practical limitations include optimization of labeling protocols and threshold settings for accurate quantification.
Biopharma FAQs
Chapters in this video
0:04
Introduction
1:00
Setup of the nFCM Instrument and Measurements of the nFCM Standards
3:47
Determining the Particle Concentration of an Unlabeled Sample and Generating a PDF Report
7:50
nFCM Analysis: PDF Generation for Subpopulation Analysis
9:26
Results: Tetraspanin Presentation on SW620 Derived EVs and C2C12 Derived EVs
12:00
Conclusion
